

# Bioprocessing of Camptothecin from *Penicillium chrysogenum*

Ashraf Sweilam\*

Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

## Introduction

Investigating the metabolic strength of organisms as camptothecin makers raises the desire for their utilization as a modern wellspring of camptothecin, because of their short-life length and the possibility of metabolic designing. In any case, the small yield and loss of camptothecin efficiency of organisms during capacity and sub-refined are difficulties that neutralize this methodology.

Malignant growth is the significant reason for death around the world, with a yearly expansion in the quantity of cases [1]. With these raised death rates, investigating novel ways to deal with malignant growth treatment is crucial. Camptothecin was first disconnected from *Camptotheca acuminata* in China. Water dissolvable camptothecin subordinations, Topotecan and Irinotecan, have been endorsed by the Food and Drug Administration (FDA) as an all-inclusive medication for ovarian, cell cellular breakdown in the lungs, colorectal carcinoma unmanageable and other metastatic colorectal tumors. The anticancer action of Camptothecin comes from its higher fondness and communication with Topoisomerase-I (Topo I), a protein that controls the DNA geography during replication, recombination and record. The topoisomerase I is normally engaged with unwinding of DNA supercoiling by making a scratch in the single strand of DNA to deliver the supercoils produced from the different replication of cancer cells, making an ester linkage with the 3' finish of scratched DNA through its synergist tyrosine [2-4]. Restraint of DNA Topo I by camptothecin causes a protein-DNA breakage in different kinds of growth cells. Camptothecin (C<sub>20</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>) has five cyclic underlying rings, three rings of pyrrolo-(3,4-β)-quinoline (A, B, and C), combined with a pyridone (ring D) at position 20, and one chiral focus inside the α-hydroxy lactone ring with (S) design (E ring).

Industrially, camptothecin is the third biggest business anticancer medication after Taxol and vincristine. Notwithstanding, there are difficulties that hinder the clinical uses of this compound. Poor water dissolvability with extreme gastrointestinal poisonousness of the center camptothecin compound is a limit which has been settled by growing profoundly water solvent camptothecin subordinations 10-hydroxycamptothecin, topotecan and irinotecan [5].

## Conclusion

Camptothecin is one of the most remarkable alkaloids for malignant growth treatment because of its extraordinary liking for restricting with DNA topoisomerase I, hindering its different natural cycles: DNA replication, RNA record and chromatin get together. Camptothecin subsidiaries are perhaps of the most usually endorsed anticancer medication, tantamount to Taxol and vincristine, chiefly removed from the plant *Camptotheca acuminata*, possessing China and India. Notwithstanding, the little yield of camptothecin from normal plant sources, hardships in extraction, the weakness of the yield of this plant to natural and biological circumstances, and the monstrous gathering of the plant making obliteration the environmental equilibrium are significant difficulties.

## Conflict of Interest

None.

## References

1. Yamazaki, Yasuyo, Mariko Kitajima, Masanori Arita and Hiromitsu Takayama, et al. "Biosynthesis of camptothecin. In silico and in vivo tracer study from [1-13C] glucose." *Plant Physiol* 134 (2004): 161-170.
2. Puri, S.C., G. Handa, B.A. Bhat and V.K. Gupta, et al. "Separation of 9-methoxycamptothecin and camptothecin from *Nothapodytes foetida* by semipreparative HPLC." *J Chromatogr Sci* 43 (2005): 348-350.
3. Lorence, Argelia, F. Medina-Bolivar and Craig L. Nessler. "Camptothecin and 10-hydroxycamptothecin from *Camptotheca acuminata* hairy roots." *Plant Cell Rep* 22 (2004): 437-441.
4. López-Meyer, Melina, C.L. Nessler and T.D. McKnight. "Sites of accumulation of the antitumor alkaloid camptothecin in *Camptotheca acuminata*." *Planta Medica* 60 (1994): 558-560.
5. Benderoth, Markus, Susanne Textor, Aaron J. Windsor and Thomas Mitchell-Olds, et al. "Positive selection driving diversification in plant secondary metabolism." *Proc Natl Acad Sci* 103 (2006): 9118-9123.

**How to cite this article:** Sweilam, Ashraf. "Bioprocessing of Camptothecin from *Penicillium chrysogenum*." *J Bioprocess Biotech* 12 (2022): 513.

\*Address for Correspondence: Ashraf Sweilam, Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, E-mail: Ashrafswailam888@gmail.com

**Copyright:** © 2022 Sweilam A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received:** 04 April, 2022, Manuscript No. Jbpb-22-68950; **Editor Assigned:** 06 April, 2022, PreQC No. P-68950; **Reviewed:** 18 April, 2022, QC No. Q-68950; **Revised:** 25 April, 2022, Manuscript No. R-68950; **Published:** 30 April, 2022, DOI: 10.37421/2155-9821.2022.12.513.